PDCD1 and neoplasm: In summary, this study demonstrates, in a range of solid tumor models, that the benefit of PD-1 blockade in adoptive T-cell therapy is driven by an effect on the endogenous T-cell repertoire and the inherent antigenicity of the tumor rather than by an effect on the transferred T cells.